Icosagen Cell Factory OÜ

Year	Period	Submitted	Status
2025	01.01.2025 – 31.12.2025	29.06.2026	Valid	PDF
2024	01.01.2024 – 31.12.2024	27.06.2025	Valid	PDF
2023	01.01.2023 – 31.12.2023	11.06.2024	Valid	PDF
2022	01.01.2022 – 31.12.2022	11.05.2023	Valid	PDF
2021	01.01.2021 – 31.12.2021	17.06.2022	Valid	PDF
2020	01.01.2020 – 31.12.2020	29.06.2021	Valid	PDF
2019	01.01.2019 – 31.12.2019	16.06.2020	Valid	PDF
2018	01.01.2018 – 31.12.2018	25.06.2019	Valid	PDF
2017	01.01.2017 – 31.12.2017	08.06.2018	Valid	PDF
2016	01.01.2016 – 31.12.2016	29.06.2017	Valid	PDF
2015	01.01.2015 – 31.12.2015	11.06.2016	Valid	PDF
2014	01.01.2014 – 31.12.2014	25.06.2015	Valid	PDF
2013	01.01.2013 – 31.12.2013	30.06.2014	Valid	PDF
2012	01.01.2012 – 31.12.2012	26.06.2013	Valid	PDF
2011	01.01.2011 – 31.12.2011	15.06.2012	Valid	PDF
2010	01.01.2010 – 31.12.2010	11.05.2011	Valid	PDF
2009	01.01.2009 – 31.12.2009	16.06.2010	Valid	PDF
2008	01.01.2008 – 31.12.2008	18.06.2009	Valid	PDF
2007	01.01.2007 – 31.12.2007	02.05.2008	Valid	PDF
2006	01.01.2006 – 31.12.2006	28.03.2007	Valid	PDF
2005	11.04.2005 – 31.12.2005	09.03.2006	Valid	PDF

Unsubmitted declarations

No unsubmitted declarations found

No unsubmitted declarations as of 14.10.2026.

Check company creditworthiness in seconds

Detailed reviews of company financial risks and strengths

3€ /monthGet started

Tax debt Reports Declarations Court decisions–Official announcements1 TTJA decisions–Real estate–.ee domains–Licenses–Regulations29 Public transactions122 Grants19 State aid77 Public procurement1 Holdings in companies–Enforcement proceedings Payment orders

Tax data

Period	State taxes	Labour taxes	Taxable turnover	Employees
2026 Q3	845 809 €	918 512 €	2,50 M €−36,8%	181
2026 Q2	859 868 €	936 603 €	3,95 M €−5,3%	176
2026 Q1	841 560 €	911 298 €	4,17 M €+43,0%	185
Total 2026:	2,55 M €	2,77 M €	10,6 M €
2025 Q4	853 895 €	920 170 €	2,92 M €−2,6%	180
2025 Q3	878 797 €	948 072 €	3,00 M €+1,6%	183
2025 Q2	877 436 €	946 108 €	2,95 M €−35,8%	184
2025 Q1	967 790 €	1,04 M €	4,59 M €+1,0%	190
Total 2025:	3,58 M €	3,85 M €	13,5 M €
2024 Q4	695 022 €	744 389 €	4,55 M €+25,2%	184
2024 Q3	746 582 €	791 527 €	3,63 M €−29,0%	175
2024 Q2	679 998 €	727 184 €	5,12 M €−12,9%	170
2024 Q1	801 431 €	852 031 €	5,88 M €−22,5%	170
Total 2024:	2,92 M €	3,12 M €	19,2 M €
2023 Q4	569 189 €	599 328 €	7,58 M €+59,4%	157
2023 Q3	551 505 €	588 218 €	4,76 M €+1,1%	148
2023 Q2	577 252 €	538 385 €	4,71 M €−15,5%	140
2023 Q1	604 233 €	640 958 €	5,57 M €+34,8%	134
Total 2023:	2,30 M €	2,37 M €	22,6 M €
2022 Q4	399 992 €	423 703 €	4,13 M €+4,9%	119
2022 Q3	391 344 €	414 445 €	3,94 M €+0,1%	116
2022 Q2	373 636 €	349 548 €	3,94 M €−18,9%	108
2022 Q1	365 682 €	389 743 €	4,85 M €+37,7%	94
Total 2022:	1,53 M €	1,58 M €	16,9 M €
2021 Q4	314 246,79 €	278 224,69 €	3,52 M €+12,7%	81
2021 Q3	316 809,51 €	248 623,61 €	3,13 M €−14,0%	78
2021 Q2	288 561,78 €	214 604,94 €	3,63 M €+100%	75
2021 Q1	260 152,20 €	278 588,13 €	1,82 M €−5,6%	68
Total 2021:	1,18 M €	1,02 M €	12,1 M €
2020 Q4	169 814,31 €	181 998,61 €	1,92 M €−6,5%	61
2020 Q3	179 653,70 €	177 857,55 €	2,06 M €+6,5%	56
2020 Q2	152 755,64 €	163 358,79 €	1,93 M €+43,2%	50
2020 Q1	196 598 €	202 182 €	1,35 M €−15,6%	50
Total 2020:	698 821,65 €	725 396,95 €	7,27 M €
2019 Q4	137 613 €	146 798 €	1,60 M €+15,2%	48
2019 Q3	128 103 €	137 644 €	1,39 M €−1,4%	49
2019 Q2	131 542 €	140 968 €	1,41 M €+35,6%	47
2019 Q1	152 833 €	163 334 €	1,04 M €+1,6%	47
Total 2019:	550 091 €	588 744 €	5,44 M €
2018 Q4	118 122 €	126 660 €	1,02 M €+42,6%	42
2018 Q3	126 307 €	135 320 €	717 003 €−27,3%	42
2018 Q2	127 319 €	135 011 €	986 295 €−0,9%	42
2018 Q1	135 489 €	145 307 €	994 836 €+44,2%	40
Total 2018:	507 237 €	542 298 €	3,72 M €
2017 Q4	93 253 €	100 481 €	690 016 €+112%	37
2017 Q3	96 549 €	103 781 €	325 193 €−57,2%	31
2017 Q2	98 853 €	103 586 €	760 434 €+39,6%	31
2017 Q1	110 540 €	118 895 €	544 745 €+9,1%	31
Total 2017:	399 195 €	426 743 €	2,32 M €
2016 Q4	86 507 €	93 438 €	499 320 €+12,4%	21
2016 Q3	77 147 €	83 142 €	444 297 €+57,0%	21
2016 Q2	52 653 €	52 953 €	282 974 €−13,9%	21
2016 Q1	56 999 €	61 467 €	328 473 €+49,7%	21
Total 2016:	273 306 €	291 000 €	1,56 M €
2015 Q4	46 319 €	49 874 €	219 372 €−1,6%	17
2015 Q3	46 992 €	50 687 €	222 950 €+11,4%	17
2015 Q2	48 233 €	45 512 €	200 185 €−26,0%	17
2015 Q1	57 054 €	61 463 €	270 348 €	17
Total 2015:	198 598 €	207 536 €	912 855 €

Revenue by industry

	2023	2024	2025
Research and experimental development on natural and technical sciences		12 578 927 €	8 393 635 €
Other services n.e.c.		337 143 €	377 908 €
Research and development in biotechnology	13 067 942 €
Other service activities	279 963 €

Tax debts

No tax debt found

No tax debt as of 14.10.2026

Representatives

	Personal ID code
Mart Ustav	34907XXXXXX	16.07.1949 (77)	Board member	03.11.2008	-

15 inactive records hidden, extended access to the information portal is required to view history!

3€ /monthGet started

Shareholders

	Personal ID code
Icosagen AS	10565884	27.08.1999 (27)	Shareholder	11 504 EUR	100,00%	Sole ownership	16.08.2023	-

15 inactive records hidden, extended access to the information portal is required to view history!

3€ /monthGet started

Other persons

	Personal ID code
Grant Thornton Baltic OÜ	10384467	18.02.1998 (28)	Audit firm	15.02.2023	-
Icosagen AS	10565884	27.08.1999 (27)	Founder	11.04.2005	-

15 inactive records hidden, extended access to the information portal is required to view history!

3€ /monthGet started

Ultimate beneficial owners

	Personal ID code
Ene Talpsep	45303XXXXXX	25.03.1953 (73)	Member of higher governing body (board or supervisory board)	29.06.2021	-
Mart Ustav	34907XXXXXX	16.07.1949 (77)	Indirect holding	18.10.2018	-

15 inactive records hidden, extended access to the information portal is required to view history!

3€ /monthGet started

Holdings in companies

No holdings in companies found

Company has no holdings in other companies

2026 Q3

Turnover

Amount: 2 499 401 €
Monthly average: 833 134 €
Per employee: 4 603 €
Equity ratio: 7 242,12%

Labour taxes

Turnover ratio: 36,75%
Tax ratio: 108,60%
Monthly average: 306 171 €
Per employee: 1 715 €

State taxes

Monthly average: 281 936 €
Turnover ratio: 33,84%

Estimated salary

Gross salary: 3 118 €
Net salary: 2 499 €

Aggregate data

Last 5 yrsAll

	2025	2024	2023	2022	2021	2020	2019
Current assets	13 324 470 €+63,2%	8 165 151 €+24,2%	6 572 660 €−48,9%	12 870 969 €+38,2%	9 313 303 €+137%	3 931 706 €+65,6%	2 374 310 €
Non-current assets	25 160 412 €+12,3%	22 401 656 €+30,6%	17 155 320 €+154%	6 741 209 €+184%	2 370 529 €+27,3%	1 861 668 €+32,9%	1 400 765 €
Total assets	38 484 884 €+25,9%	30 566 808 €+28,8%	23 727 980 €+21,0%	19 612 178 €+67,9%	11 683 832 €+102%	5 793 374 €+53,5%	3 775 075 €
Short-term liabilities	5 535 535 €+22,9%	4 504 353 €−20,5%	5 663 753 €+64,0%	3 453 448 €+79,9%	1 919 486 €+65,0%	1 163 024 €+29,3%	899 155 €
Long-term liabilities	18 830 282 €+149%	7 559 025 €+1 749%	408 830 €−58,2%	979 187 €+77,2%	552 563 €−26,5%	751 550 €+1,4%	740 996 €
Total liabilities	24 365 817 €+102%	12 063 378 €+98,7%	6 072 583 €+37,0%	4 432 635 €+79,3%	2 472 049 €+29,1%	1 914 574 €+16,7%	1 640 151 €
Share or stock capital	-	-	-	-	-	-	-
Retained earnings	18 369 728 €+4,8%	17 522 844 €+16,5%	15 046 991 €+65,7%	9 079 231 €+142%	3 746 248 €+87,1%	2 002 372 €+54,3%	1 297 943 €
Net profit	-4 384 364 €−617%	848 033 €−65,7%	2 475 854 €−58,5%	5 967 760 €+11,9%	5 332 983 €+206%	1 743 876 €+148%	704 429 €
Equity	14 119 066 €−23,7%	18 503 430 €+4,8%	17 655 396 €+16,3%	15 179 543 €+64,8%	9 211 783 €+137%	3 878 800 €+81,7%	2 134 924 €
Turnover	8 771 543 €−32,1%	12 916 070 €−3,2%	13 347 905 €−2,4%	13 677 072 €+19,1%	11 485 743 €+72,0%	6 679 291 €+40,1%	4 767 928 €
Profit margin	-50,0%	6,6%	18,5%	43,6%	46,4%	26,1%	14,8%

Financial ratios

	2022	2021
Profit and cash flow
EBITDA	6 839 720 €	5 744 150 €
Liquidity
Current ratio	3,7	4,9
Quick ratio	3,7	4,8
Cash ratio	2,3	3,4
Efficiency
Days sales outstanding (dso)	105,1	75,2
Asset turnover	0,9	1,3
Structure
Debt ratio	0,2	0,2
Profitability
Operating margin	43,4%	46,1%
Net profit margin	43,6%	46,4%
Return on assets (roa)	38,1%	61,0%
Return on equity (roe)	39,3%	57,9%

Data export

These figures for over 281,000 companies, in one table

Revenue, EBITDA, ROE, ROA and other ratios
Up to five years of reports at once
Excel, CSV or JSON, updated daily

See how it works

To view all financial ratios, you need to subscribe to extended access to the info portal!

3€ /monthGet started

Licences & notices

No licenses and notices found

Company has no active licenses and business activity notices

Regulations


Ä 20028773 / 22	11.05.2023	Entry – Amendment entry	-	Entered into force11.05.2023
K 20028773 / 21	13.12.2022	Entry – Commercial-pledge amendment entry	-	Entered into force13.12.2022
K 20028773 / M5	08.12.2022	Order to remedy deficiencies – Commercial-pledge amendment entry	23.12.2022	Deficiencies remedied13.12.2022
Ä 20028773 / 20	25.06.2019	Entry – Amendment entry	-	Entered into force25.06.2019
Ä 20028773 / 19	17.01.2018	Entry – Amendment entry	-	Entered into force17.01.2018

Real estate

No real estate found

Company has no real estate

Consumer Disputes Committee decisions

No consumer dispute committee decisions found

Company has not been issued consumer dispute committee decisions

Court decisions

No court decisions found

The company has no court decisions

Official announcements


Geneetiliselt muundatud organismi keskkonda viimise loa andmise menetluse alustamise teade	12.10.2026	PDF

Public transactions


04.09.2026	Tartu Ülikool	2 253,08 €Received	OPERATING EXPENSESTertiary education
15.07.2026	Sihtasutus Eesti Teadusagentuur	135 000 €Received	OTHER GRANTSR&D in education
15.07.2026	Majandus- ja Kommunikatsiooniministeerium	256 527,74 €Received	OTHER GRANTSR&D in general economic, trade and labour policy
13.07.2026	Majandus- ja Kommunikatsiooniministeerium	209 804,72 €Received	OTHER GRANTSR&D in general economic, trade and labour policy
13.07.2026	Majandus- ja Kommunikatsiooniministeerium	202 084,28 €Received	OTHER GRANTSR&D in general economic, trade and labour policy

Funded projects


Icosagen Cell Factory digitaliseerimise teekaardi elluviimine20.1.01.23-0408	Majanduse digipöörde toetamineRRF · Ettevõtluse ja Innovatsiooni Sihtasutus	01.09.2023 – 30.04.20252020-2026	594 850,06 €support 49,7%	546 713,66 €	Completed
Icosagen Cell Factory OÜ digitaliseerimise teekaardi koostamine2014-2020.4.04.23-2542	Ettevõtja arenguplaani toetusmeede ettevõtete arendus- ja eksporditegevustele kaasaaitamiseks ning juhtimisvõimekuse tõstmiseksERDF · Ettevõtluse ja Innovatsiooni Sihtasutus	20.02.2023 – 30.06.20232014-2020	18 900 €support 70,0%	18 900 €	Completed
An immune stimulatory approach to vaccination against coronavirus (ICOISR)2014-2020.15.03.21-0120	Majanduse elavdamineREACT-EU · Ettevõtluse ja Innovatsiooni Sihtasutus	01.09.2021 – 31.08.20232014-2020	600 657 €support 50,0%	513 012,60 €	Completed
Development of therapeutic IgA molecules and expression platform for SARS-CoV (sIgA-Covid)2014-2020.4.02.21-0314	TA&I süsteemi kohaliku sotsiaalmajandusliku mõju suurendamine ja nutikas spetsialiseerumine kasvualade (IKT + tervis + ressursid) arendamiseksERDF · Ettevõtluse ja Innovatsiooni Sihtasutus	01.02.2021 – 31.12.20232014-2020	3 689 844,19 €support 79,9%	3 687 437,47 €	Completed
Tehnoloogilise alusplatvormi arendamine SARS-COV-2 ja teisi respiratoorseid viiruseid neutraliseerivate preparaatide loomiseks hüperimmuniseeritud lehmade ternespiimast (BioMask)2014-2020.4.02.21-0317	TA&I süsteemi kohaliku sotsiaalmajandusliku mõju suurendamine ja nutikas spetsialiseerumine kasvualade (IKT + tervis + ressursid) arendamiseksERDF · Ettevõtluse ja Innovatsiooni Sihtasutus	01.02.2021 – 16.11.20232014-2020	2 636 436,12 €support 79,9%	2 636 427,12 €	Completed

State aid


18.03.2026	Ettevõtluse ja Innovatsiooni SihtasutusAid measure 241718	T&A VTA › T&A VTAGrant	36 436,69 €	241718/2600073
18.03.2026	Ettevõtluse ja Innovatsiooni SihtasutusAid measure 241718	T&A VTA › T&A VTAGrant	9 009,98 €	241718/2600074
07.10.2025	Ettevõtluse ja Innovatsiooni SihtasutusAid measure 241718	T&A VTA › T&A VTAGrant	1 581,93 €	241718/2500331
03.10.2025	Ettevõtluse ja Innovatsiooni SihtasutusAid measure 241718	T&A VTA › T&A VTAGrant	18 107,69 €	241718/2500317
03.10.2025	Ettevõtluse ja Innovatsiooni SihtasutusAid measure 241718	T&A VTA › T&A VTAGrant	17 261,71 €	241718/2500319

Public procurement contracts


16.11.2010End 30.04.2011	Reference number 121759 · 13121K1	Tartu ÜlikoolContracting authority	27 302,80 €	Completed

.ee domains

No domains found

Company has no valid .ee domains

Enforcement proceedings

No enforcement proceedings found

Company has no active debts with bailiffs

Payment orders

No payment orders found

Company has no court-ordered payment orders

Data comes from public registers.